Presentations from Top Biopharma (2021)


Therapeutic Biologics: Challenges in Production and Analytics for Discovery
John E. Harlan, PhD, Senior Group Leader, AbbVie


Application of Mammalian Display Coupled with In Vitro Antibody Library Technology to Membrane Protein Multi-Spanner Targets
Agnieszka Kielczewska, PhD, Senior Scientist, Antibody Discovery, Amgen, Inc.

Determination of Interactions between Antibody Biotherapeutics and Copper by Size Exclusion Chromatography (SEC) Coupled with Inductively Coupled Plasma Mass Spectrometry (ICP/MS)
Yanxin Luo, PhD, Scientist, Process Development, Amgen

In Vivo Serum Reversibility Assay for Assessing the Impact of Aggregates and HMW
Cathie Xiang, Scientist, Attribute Science, Amgen, Inc.

Rethinking HT Biologics Workflows from Screening to Scale Up: Automation, Informatics and Comprehensive Analytics
Daniel Yoo, Senior Scientist, Therapeutic Discovery, Amgen, Inc.


Talk Title to be Announced
Changshou Gao, PhD, Senior Director & Fellow, Antibody Discovery & Protein Engineering, AstraZeneca Biologics

Understanding the Mechanism of Surface-Mediated Protein Aggregation
Cavan Kalonia, PhD, Scientist II, Formulation, AstraZeneca Biologics

Effect of Photo-Induced Protein Radicals on Cis/Trans Isomerization of Unsaturated Fatty Acids in Polysorbate 80
Indira Prajapati, PhD, Scientist I, AstraZeneca

Potential Use of Transient Gene Expression to Generate Clinical-Grade Material
Sara Rodriguez Conde, PhD, Cell Culture & Fermentation Sciences, Biopharmaceuticals Development, R&D, AstraZeneca


Analytical Method Development for the Characterization of AAV-Based Products: Challenges and Outcomes
George Bou-Assaf, PhD, Scientist, Analytical Development – Product & Technology Development, Biogen

Sequence Variant and Post-Translational Modification Analysis during Cell Line Selection via High-Throughput Peptide Mapping and Intact Mass Analysis
Chongfeng Xu, PhD, Senior Scientist, Biogen

Assessment of a Stabilized Sporicidal Solution for Affinity Resins
Maria Znidarsic, Engineer I, Downstream Development, Biogen

Boehringer Ingelheim

Loss of a Newly Identified Small Non-Coding RNA Leads to Increased NGNA (Neu5Gc) Sialylation of Monoclonal Antibodies in CHO Cells
Simon Fischer, PhD, Head, Cell Biology, Boehringer Ingelheim

Bristol-Myers Squibb

Ambient Light and UV Emission: Effect of Protein Concentration and Surface-Exposed Tryptophan on Monoclonal Antibody Aggregation
Haresh T. More, PhD, Senior Research Investigator I, Bristol-Myers Squibb

Leveraging Automation to Enable High-Concentration Formulation Development
Peter Soler, PhD, Senior Research Investigator, Bristol-Myers Squibb Co.

Shortening Speed to Clinic through Use of Polyclonal Cells for IND-Enabling Toxicology Studies
Gabi Tremml, PhD, Associate Director, Cell Line Development, Bristol-Myers Squibb Co.


Characterization of Cyclic Peptide Aggregation Behavior Using Biophysical, Intact Mass, and Top-Down Disulfide Mapping Approaches
Elizabeth S. Hecht, PhD, Associate Scientist, Microchemistry, Proteomics & Lipidomics, Genentech

Key Learnings and Approaches for Establishing a High-Throughput, Multi-Host Protein Expression Testing and Purification Platform for All Protein Types
Edward Kraft, PhD, Senior Scientific Manager, BioMolecular Resources, Genentech


High-Throughput, Efficacious Gene Editing & Genome Surveillance in Chinese Hamster Ovary Cells
Zhimei Du, PhD, Director, Biologics & Cell Therapeutics Process Development, Merck

Structure and Characterization of Monoclonal Antibody Self-Association Complex Reveals Specific Face-to-Face Interaction: Developability and Predictive Implications
Carl Mieczkowski, PhD, Associate Principal Scientist, Protein Sciences, Merck Research Labs

bioPROTACs Establish RAS as a Degradable Target and Provide Novel RAS Biology Insights
Anthony Partridge, PhD, Senior Principal Scientist, Merck Sharp & Dohme, Singapore


Platformization of Multi-Specific Protein Engineering IV: Realization of Challenging Multi-Specific Target Protein Profiles through Format Agnostic, Ultra High-Throughput Variant Profiling
Joerg Birkenfeld, PhD, Head, High Throughput Biologics, Sanofi Germany GmbH

Platformization of Multi-Specific Protein Engineering: Leveraging High-Throughput Screening Data for in silico Antibody Design
Norbert Furtmann, PhD, Section Head, Data Science & Computational Design, Biologics Research, Sanofi, Germany

Challenges in Developing Gene Delivery Products
Andrew Kroetsch, PhD, Sr Scientist, Biologics Drug Product Development, Sanofi

Evolution of Hyphenated Chromatographic Methods for Characterization of Polysorbate 80 to Support Product Understanding and Formulation Development
He Meng, Senior Scientist, Analytical Development, Sanofi

Engineered Fc-Glycosylation Switch to Eliminate Antibody Effector Function
Qun Zhou, PhD, Senior Principal Scientist, US Biologics Research, Sanofi Genzyme R&D Center